Xtant Medical (XTNT) Stock Price, News & Analysis

Company Overview

Xtant Medical, Inc. is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents. Xtant Medical leverages proprietary technologies to optimize handling characteristics and osteoinductive potential, with products that are used by surgeons in hospital operating rooms and outpatient surgical centers. The company also provides custom solutions through its product design and contract manufacturing services.

Headquartered in Carlsbad, California, Xtant Medical serves customers primarily across North America, with distribution partnerships extending to select international markets. Under the leadership of President and Chief Executive Officer Shawn Ainsworth, the company continues to expand its research and development capabilities and advance its regenerative medicine pipeline. Xtant Medical is dedicated to improving patient outcomes by delivering innovative, clinically driven solutions for spinal and orthopedic care.

Key Stats

• Today's Range: $0.43 to $0.43
• 50-Day Range: $0.43 to $0.58
• 52-Week Range: $0.40 to $0.95
• Volume: 49,250 shs
• Average Volume: 111,374 shs
• Market Capitalization: $59.96 million
• P/E Ratio: 42.79
• Dividend Yield: N/A
• Price Target: $1.00
• Consensus Rating: Buy

Xtant Medical Stock Analysis - MarketRank™

Xtant Medical scored higher than 62% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Xtant Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Xtant Medical has a consensus price target of $1.00, representing about 133.9% upside from its current price of $0.43.

Amount of Analyst Coverage

Xtant Medical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Xtant Medical is 42.79, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.83.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xtant Medical is 42.79, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.71.

Price to Book Value per Share Ratio

Xtant Medical has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Xtant Medical has been sold short.

Short Interest Ratio / Days to Cover

Xtant Medical has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Xtant Medical has recently decreased by 80.15%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xtant Medical does not currently pay a dividend.

Dividend Growth

Xtant Medical does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Xtant Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.40% of the stock of Xtant Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

69.33% of the stock of Xtant Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/13/2026
• Today: 6/23/2026
• Next Earnings (Estimated): 7/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:XTNT
• Previous Symbol: AMEX:XTNT
• CIK: 1453593
• Web: xtantmedical.com
• Phone: (406) 388-0480
• Fax: 406-388-1354
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Xtant Medical: $1.00
• High Price Target: $1.00
• Low Price Target: $1.00
• Potential Upside/Downside: +133.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.13)
• Trailing P/E Ratio: 42.79
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $4.97 million
• Net Margins: 1.50%
• Pretax Margin: 3.20%
• Return on Equity: 3.68%
• Return on Assets: 1.91%

Debt

• Debt-to-Equity Ratio: 0.17
• Current Ratio: 3.34
• Quick Ratio: 1.64

Sales & Book Value

• Annual Sales: $133.93 million
• Price / Sales: 0.45
• Cash Flow: $0.07 per share
• Price / Cash Flow: 5.99
• Book Value: $0.36 per share
• Price / Book: 1.19

Miscellaneous

• Outstanding Shares: 140,260,000
• Free Float: 125,676,000
• Market Cap: $59.96 million
• Optionable: Not Optionable
• Beta: -0.16